A Study of ARRY-334543 in Patients With Advanced Cancer

Phase 1

Completed

Brief Summary: This is a Phase 1 study during which patients with advanced solid tumors will receive a new formulation of investigational study drug ARRY-334543. Patients will receive increasing doses of study drug in order to achieve the highest dose possible that will not cause unacceptable side effects. The patients will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. In addition, the effect of food on the new formulation will be evaluated. Approximately 24 patients from Canada will be enrolled in this study (Active, not recruiting).

Recruitment & Eligibility

Inclusion Criteria

Histological or cytological evidence of malignancy.
Patients with advanced solid tumors who are no longer candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
Cardiac ejection fraction ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition (MUGA).
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
Additional criteria exist.

Key

Exclusion Criteria

Uncontrolled brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days).
Use of an investigational medication or device within 30 days prior to first dose of study drug.
Major surgery within 30 days prior to first dose of study drug.
Radiotherapy or chemotherapy within 28 days prior to first dose of study drug (not including palliative radiotherapy at focal sites).
Active, uncontrolled infection requiring systemic antibiotic therapy or other serious underlying medical condition which would impair the ability of the patient to receive protocol treatment.
Pregnancy or lactation.
Known positive serology for the human immunodeficiency virus (HIV), 'active' hepatitis B and/or hepatitis C.
Additional criteria exist.

Arm && Interventions

Group	Intervention	Description
ARRY-334543	ARRY-334543, EGFR/ErbB2 inhibitor; oral	-

Primary Outcome Measures

Name	Time	Method
Characterize the pharmacokinetics (PK) of the new formulation of study drug (in terms of plasma concentrations) when administered in a fed versus fasted state.	Day 1 and Day 8
Characterize the safety profile of the new formulation of study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.	Duration of study
Establish the maximum tolerated dose (MTD) of the new formulation of study drug.	Duration of study
Assess the exposure of the new formulation of study drug in terms of plasma concentrations.	Duration of study

Secondary Outcome Measures

Name	Time	Method
Assess the efficacy of the new formulation of study drug in terms of tumor dimension assessment.	Duration of study

Locations (2): Ottawa Hospital Cancer Centre
🇨🇦
Ottawa, Ontario, Canada
Juravinski Cancer Center at Hamilton Heath Sciences
🇨🇦
Hamilton, Ontario, Canada